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Abstract. Crush syndrome (CS), a serious medical condi-
tion, which is characterized by damage to myocytes due to 
pressure and is associated with high mortality, even when 
patients receive fluid therapy. Icing therapy over the affected 
muscle has been reported to be effective in improving mito-
chondrial dysfunction and inflammation. These effects are 
thought to be secondary to improvements in the leakage 
of potassium and myoglobin from the damaged myocytes 
in the early stages of disease. However, their effects on the 
various symptoms of CS are unclear. It was hypothesized 
that treatment with icing will inhibit the influence of potas-
sium by vasoconstriction, exert anti‑inflammatory effects in 
the affected myocytes and improve mitochondrial function 
The CS model constructed by subjecting anesthetized rats 
to bilateral hindlimb compression with a rubber tourniquet 
for 5 h. The rats were then randomly divided into six groups: 
i) Sham; ii) CS without treatment (CS); iii) and iv) icing for 
30 or 180 min over the entire hindlimb on CS rats (CI-30 
and ‑180), respectively; and v) and vi) local icing for 30 or 
180 min over the affected area on CS rats (CLI‑30 and ‑180), 
respectively. Under continuous monitoring and recording 
of arterial blood pressures, blood and tissue samples were 
collected for biochemical analyses at designated time points 
prior to and following reperfusion. The survival rate, vital 
signs, and blood gas parameters in the CS group were lethal 
compared with the sham group. These were also improved in 
the CI-30 and CLI-30 groups compared with the CS group; 
however, they worsened in the CI-180 and CLI-180 groups 
due to hypothermia. The CI‑30 and CLI‑30 groups demon-
strated tendencies of improvements compared with the CS 
group. Systemic inflammation and mitochondria dysfunction 
had improved in these groups compared with the CS group. 
We suggest icing therapy to temporarily prolong the viability 
after crush injury. Its effectiveness can be improved by 
combining it with other infusion therapies.
Introduction
Crush syndrome (CS) is a systemic dysfunction resulting from 
crush injuries and muscle compression. It is characterized by 
an unpredictable clinical course and high mortality due to 
cardiac arrest, shock, acute kidney injury (AKI), and inflam-
matory disorders (1‑3). Several human and animal studies have 
included pathological analyses of CS. In disaster management, 
massive fluid resuscitation is the recommended initial manage-
ment to prevent death due to cardiac arrest and AKI. However, 
CS is known as rescue death because approximately 20% of 
deaths occur shortly after extrication (4), and at a hospital, 
these patients are at an additional risk of systemic inflamma-
tory response syndrome and multi organ dysfunction syndrome 
secondary to ischemia reperfusion due to the recommended 
therapy. We previously reported that in a CS model involving 
rats (5), they died due to cardiac failure following hyperka-
lemia; therefore, the outcomes in patients with CS might be 
improved by improving the condition of the muscles involved. 
Furthermore, improvements in the muscles are reported to be 
due to the anti‑inflammatory and anti‑oxidative effects that 
follow prevention of mitochondrial dysfunction (6).
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Cryotherapy involves the cooling via ice packs or similar 
methods of the skin overlying the respective muscles in order 
to temporarily reduce muscle temperature, induce vasocon-
striction, and inhibit pain sensation. The potential benefits of 
cryotherapy in the healing of the muscle following various 
trauma‑induced damages are controversial (7). In cryotherapy, 
icing technique is general used in the emergency treat-
ment of trauma in addition to rehabilitation and surgery (8). 
Furthermore, low tissue temperature is the most powerful 
intervention towards limiting ischemia reperfusion injury (IRI), 
which may subsequently prevent mitochondrial damage and, 
therefore, reduce the severity of IRI (9). Basic animal studies 
have proved the positive effect of icing treatment over contu-
sion injury (10) and crush injury in rats (11) in the early stages 
of attenuated inflammation (during migration of inflammatory 
cells); however, these effects were not sufficient to prevent 
effective muscle regeneration at later stages. Furthermore, 
such studies did not investigate and clarify the efficacy of icing 
intervention in improving survival, electrolyte balance, vital 
signs, and inflammation at early stages within 24 h.
In the present study involving CS model rats, we hypoth-
esized that treatment with icing will inhibit the influence of 
potassium by vasoconstriction, exert anti‑inflammatory effects 
in the affected myocytes, and improve mitochondrial function. 
Materials and methods
Animal model of CS. Male Wistar rats, weighing 250-300 g 
each, were obtained from Japan SLC (Shizuoka, Japan) and 
housed in a room that was maintained at a temperature of 
23±3˚C and relative humidity of 55±15% with 12:12‑h light/dark 
cycle, with free access to food and water. The animal experi-
ments were carried out according to the guidelines for animal 
use and were approved by the Life Science Research Center of 
Josai University (approval no. H29030). In the experimental 
periods, rats were anesthetized using sodium pentobarbital 
(50 mg/kg body weight, intraperitoneal [i.p.] administration). 
Anesthesia was maintained (confirmed by normal rectal 
temperature, respiratory rate, and sleeping state) by the i.p. 
administration of sodium pentobarbital (20 mg/kg body 
weight/h). The body temperature was maintained uniformly 
throughout the experiment using a heating pad. The CS rat 
model has been previously described in detail (5). Briefly, a 
rubber tourniquet was applied to both the hindlimbs of each 
rat, which was wrapped five times around a 2.0 kg‑metal 
cylinder, and the end of the band was glued. After compression 
for 5 h, it was released by cutting the band and removing the 
rubber tourniquet (i.e., reperfusion 0 h).
Experimental design. Experimental design-1 (survival rate): 
To examine the survival period and the changes in the blood 
pressure and blood gas parameters of CS rats, they were 
randomly divided into the following six groups: i) Sham 
(n=10); ii) CS (n=10); iii) icing for 30 min over the entire 
hindlimb (CI‑30)(n=10); iv) icing for 180 min over the entire 
hindlimb (CI‑180)(n=10); v) local icing for 30 min over the 
hindlimb (CLI‑30)(n=10); and (vi) local icing for 180 min 
over the hindlimb (CLI‑180) (n=10). All the rats used in the 
experiments were euthanized (confirmation by pupillary reflex 
to light) by sodium pentobarbital overdose (100 mg/kg body 
weight, intravenous administration) at 48 h after all measure-
ments were recorded.
Experimental design-2 (vital signs and blood gas param-
eters): To examine the changes in the blood pressure and 
blood gas parameters, the rats were randomly divided into 
the following six groups (n=4 each):i) sham; ii) CS; iii) CI‑30; 
iv) CI‑180; v) CL‑30; and (vi) CLI‑180 groups. Sequential 
sampling was performed at 0.083, 0.5, 1, 3, 6, and 24 h after 
reperfusion.
Experimental design‑3 (blood perfusion in the crushed 
hindlimb): blood perfusion in the crushed hindlimb was evalu-
ated with the rats divided into the following four experimental 
groups (n=6 each): i) sham; ii) CS; iii) CI‑30; and iv) CLI‑30. 
Sequential measuring was performed at 0.083, 0.5, 1, 3, 6 and 
24 h after reperfusion. All the rats used in the experiments 
were euthanized (confirmation by pupillary reflex to light) 
by sodium pentobarbital overdose (100 mg/kg body weight, 
intravenous administration) at 24 h after all measurements 
were recorded.
Experimental design‑4 (plasma potassium (K+) and 
creatine phosphokinase (CPK) levels, and anti‑inflammatory 
and mitochondrial function parameters): Biochemical anal-
yses, serum cytokine levels, and mitochondrial parameters 
were evaluated with the rats divided into the following four 
experimental groups (n=6 each): i) Sham; ii) CS; iii) CLI‑30; 
and (iv) CLI‑180. Samplings were performed at 1, 3, 6 and 
24 h after reperfusion. All the rats used in the experiments 
were euthanized (confirmation by pupillary reflex to light) 
by sodium pentobarbital overdose (100 mg/kg body weight, 
intravenous administration) at each sampling time.
Vital signs, blood gas levels, and biochemical parameters. 
The following vital signs were recorded using a PowerLab 
data acquisition system (AD Instruments, Nagoya, Japan): 
Mean blood pressure (MBP), heart rate (HR), and body 
temperature (BT). One carotid artery was cannulated with a 
polyethylene catheter (PE-50 tubing) and was connected to a 
pressure transducer. Arterial blood samples from each group 
were obtained at 0.083, 0.5, 1, 3, 6, 12, and 24 h after reperfu-
sion using the carotid artery catheter (6). The arterial levels of 
hematocrit (Hct), pH, base excess (BE), anion gap (AG), and 
lactate were analyzed using i-STAT300F blood gas analyzer 
and CG4+ and EC8+ cartridges (FUSO Pharmaceutical 
Industries, Osaka, Japan). These measurements were assess 
using experimental design‑2.
Venous blood from the jugular vein was collected and 
centrifuged to measure plasma K+ and CPK (the measurements 
were carried out by SRL Inc., Tokyo, Japan). These measure-
ments were performed using experimental design‑3.
Blood perfusion parameters. Blood perfusion (BPF) of 
muscles and blood vessels was measured using PeriScan 
PIM3 (PERIMED, Stockholm, Sweden) in experimental 
design‑3. BPF was assessed under the following condi-
tions: distance to hindlimb: 10-15 cm; measurement area: 
10x10 cm; environmental temperature: 23±5˚C; and relative 
humidity: 50±5%.
Determination of cytokines, reactive oxygen species (ROS) 
production, and mitochondrial function. The serum high 
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mobility group box 1 (HMGB1), interleukin‑6 (IL‑6), and 
interleukin-10 (IL-10) were measured using HMGB1 ELISA 
Kit II (Shino‑Test Co., Tokyo, Japan), Rat IL‑6 Quantikine® 
ELISA kit (R&D Systems, Inc., MN, USA), and Rat IL‑10 
Quantikine® ELISA kit (R&D Systems, Inc., MN, USA) 
according to the manufacturer's instructions. ROS produc-
tion in the injured gastrocnemius muscle was determined by 
measuring the concentration of thiobarbituric acid reactive 
substances (TBARS) (6). Myeloperoxidase (MPO) activity 
was determined by the method previously described by 
Murata et al (6). Isolation of mitochondria from the injured 
muscles for evaluation of mitochondrial function was 
performed using a mitochondrial isolation kit (Thermo Fisher 
Scientific K.K., Kanagawa, Japan). In mitochondrial perme-
ability transition, mitochondrial membrane potential (i.e., 
mitochondrial inner membrane function) was evaluated using 
JC-1 Mitochondrial Membrane Potential Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). To evaluate the 
mitochondrial outer membrane function, cytochrome c (cyt c) 
in the cytoplasm of the crushed myocytes from the samples that 
did not include mitochondria was quantified using Quantikine® 
cyt c Immunoassay (R&D Systems, Inc. MN, USA). These 
measurements were performed using experimental design‑4 
with samples collected from the hindlimb muscles at 1, 3, 6 
and 24 h after reperfusion.
Statistical analyses. Results are expressed as means ± standard 
error of mean (SEM). Differences between the groups were 
assessed by analysis of variance with Tukey's honest significant 
difference test or Tukey's test. Survival curves were generated 
using the Kaplan-Meier method, and survival was compared 
by the log‑rank test. P<0.05 was considered to indicate a 
statistically significant difference (Statcel 2, 2nd ed. OMS 
Publishing Inc., Saitama, Japan).
Results
The impact of icing on CS rat viability. The survival rate is 
illustrated in Fig. 1. The survival rates of rats in the CS group 
were 91%, 82%, 36%, 13%, and 13% at 1, 3, 6, 24, and 48 h 
after reperfusion, respectively. Until 6 h after reperfusion, the 
survival rates in CI-30, CI-180, CLI-30, and CLI-180 groups 
were significantly higher than those in the CS group. Until 
24 h after reperfusion, the survival rates in the CI‑30 and 
CLI‑30 groups were significantly higher than those in the CS 
group; however, 48 h after reperfusion, the survival rates were 
not significantly different. Furthermore, icing for 180 min 
(CI-180 and CLI-180 groups) demonstrated a tendency to 
extend the survival period when compared with an icing 
period of 30 min (CI‑30 and CLI‑30 groups). Furthermore, the 
survival rates following icing for 5 and 60 min were similar 
to that following an icing period of 30 min (data not shown).
Icing treatment improves vital signs. The relationship between 
BT and lactate levels, and MBP and HR is illustrated in Fig. 2. 
BT in the CS group was significantly lower than that in the 
sham group at 24 h after reperfusion (31±1.4 vs. 36±0.5˚C, 
P<0.05), and the lactate level in the CS group was significantly 
higher than that in the sham group throughout the experi-
mental period. In the CI‑30 and CLI‑30 groups, BT levels 
were not significantly different when compared with that in 
the CS group until 6 h after reperfusion, and similarly than 
the sham group (37±0.2 and 36±0.4˚C), and lactate levels 
were not showed significantly changes compared that the 
CS group. In the CI‑180 and CLI‑180 groups, the BT levels 
were significantly lower than that in the CS groups at 3 h after 
reperfusion (27±0.9 and 28±2.3 vs. 35±0.5˚C, P<0.05), and the 
lactate levels were significantly higher (7.6±0.9 and 6.9±1.0 vs. 
4.5±0.4 mmol/l, P<0.05). In the CS group, MBP and HR levels 
were significantly lower than that in the sham group until 24 h 
after reperfusion (MBP, 42.8±3.8 vs. 123.2±3.1 mmHg; HR, 
231±20 vs. 390±64 bpm; P<0.05 at 24 h after reperfusion). In 
the CI-30, CLI-30, CI-180, and CLI-180 groups, MBP levels 
were significantly higher than that in the CS group until 24 h 
after reperfusion (CI‑30, 57.9±8.9; CLI‑30, 64.4±7.7; CI‑180, 
73.3±4.1; CLI‑180, 67.2±4.2 mmHg), and the HR levels were 
the CI-30 and CLI-30 group has similarly than the sham 
group until 24 h after reperfusion (CI‑30, 362±25; CLI‑30, 
352±7 bpm) however that the CI-180 and CLI-180 group 
were similar in the CS group at 6 h after reperfusion (CI‑180, 
293±18; CLI‑180, 322±9 bpm) and significantly decreased 
compared to the CI‑30 and CLI‑30 groups.
Blood gas parameters and Hct levels of all the experi-
mental groups are presented in Table I. pH and BE levels in 
the CS groups were significantly lower than that in the sham 
group, while the Hct level was significantly higher than that 
in the sham group. In the CI‑30 and CLI‑30 groups, pH level 
significantly increased compared to the CS group at 6 and 24 h 
after reperfusion; however, the CI‑180 and CLI‑180 groups had 
worse outcomes compared with the CS group until 0.083 to 
1 h after reperfusion.
Icing treatment attenuated hyperkalemia by controlling BPF. 
The survival rates, vital signs, and blood gas parameters 
Figure 1. The impact of icing of varying durations on CS rat viability. 
Open circle: Sham group; closed circle: CS group; closed triangle: CI-30 
group; open triangle: CI-180 group; closed diamond: CLI-30 group; and 
open diamond: CLI‑180 group. *; vs. sham group (P<0.05), #; vs. CS group 
(P<0.05) (log‑rank test). CS, crush syndrome; CI, icing over the entire 
hindlimb; CLI, local icing.
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improved when the the icing period was over 30 min. Further, 
an icing period of 180 min induces hypothermia; therefore, we 
decided that the icing period should be 30 min.
The plasma K+ and CPK levels and BPF of the crushed 
limbs is presented in Fig. 3. CS group had significantly 
higher plasma K+ and CPK levels than the sham group at all 
experimental periods, while the same in the CI-30 and CLI-30 
groups were significantly lower than that in the CS group at 
24 h after reperfusion. In the CS group, BPF level within the 
blood vessels was not significantly different from that in the 
sham group, and the muscle BPF level was significantly lower 
than that in the sham group at all experimental periods. In the 
CI-30 and CLI-30 groups, BPF within the blood vessels was 
significantly lower than that in the CS group at 0.5 and 1 h 
after reperfusion, while the muscle BPF level was similar to 
that in the CS group between 0.5‑6 h after reperfusion.
Icing treatment attenuated inflammation through prevention 
of mitochondrial dysfunction. The serum cytokine levels, 
and TBARS (i.e., ROS generation level) due to mitochondrial 
dysfunction is presented in Figs. 4 and 5. The CS group had 
significantly higher serum IL‑6 and IL‑10 levels than the 
sham group at 3, 6, and 24 h after reperfusion, and showed 
maximum levels at 6 h after reperfusion. Serum HMGB1 and 
MPO levels in the CS group were significantly higher than 
that in the sham group at 3‑24 h after reperfusion. Their levels 
in the CI‑30 and CLI‑30 groups were significantly lower than 
that in the CS group (Fig. 4). While evaluating the mitochon-
drial function, TBARS level in the CS group was maximum 
at 6 h after reperfusion and was significantly higher than that 
in the sham group at 3 and 6 h after reperfusion. Furthermore, 
JC‑1 fluorescence (mitochondrial membrane potential) and 
mitochondrial cyt c content in the CS group was significantly 
lower than that in the sham group at all experimental time-
points, and cytoplasm cyt c content of the CS group was lower 
than that in the sham group. In the CI‑30 and CLI‑30 groups, 
TBARS levels were significantly lower than that in the CS 
group at 3 and 6 h after reperfusion, JC‑1 fluorescence was 
significantly higher than that in the CS group at 6 and 24 h 
after reperfusion, and mitochondrial cytochrome C contents 
were significantly increased and cytoplasm cytochrome C 
contents tended to be decreased compared with those in the 
CS group (Fig. 5).
Discussion
A variety of modalities are used to treat muscle injuries 
including (7) cryotherapy, massage therapy, and hyperbaric 
oxygen therapy; however, icing is the mainstay treatment for 
several types of acute musculoskeletal injuries (12,13).
We selected the icing method since icing periods of both 
30 and 180 min decrease the average temperature of the 
skin (32‑28˚C) by 3‑5˚C (data not shown). In this study, BT 
significantly decreased only with an icing period of 180 min. 
Previous studies reported that ice application of 30 min over 
the Achilles (14) and patellar (15) tendons decreased the 
skin temperature to approximately 17‑20˚C. Furthermore, 
Dewhurst et al (16) reported that ice pack application over the 
thigh decreases skin temperature by 6˚C and muscle tempera-
ture by 4˚C. Similarly, in our study, the icing procedure was 
able to be cool the injured muscle. Knight et al (8), suggested 
that the effects of local cooling were limited to local effects; 
however, it appears to be not so according to this study. An 
icing period of 30 min did not decreased BT; however, an icing 
period of 180 min did significantly decrease BT. This might 
be because of additional factors such as increased lactate and 
decrease HR because the gastrocnemius is a relatively large 
muscle in the rat. Additionally, the vasoconstriction in the 
affected part induced by icing would decrease the release of 
potassium into the systemic circulation. We demonstrated that 
hyperkalemia can be improved from blocking the blood flow 
to the crushed limbs (data not shown). In the present study, 
we demonstrated that the blood flow to the affected limb 
temporarily decreases with icing treatment (Fig. 3D), and 
that these changes had similar effects on decreasing serum 
potassium in the experimental period (Fig. 3A). In contrast, 
Figure 2. Icing treatment improves vital signs. a) The relationship between BT and lactate levels, (B) the relationship between MBP and HR levels. The line 
graph is compares BT and MBP, while the bar graph lactate and HR levels. Open circle and white bar: Sham group; closed circle and black bar: CS group; 
closed triangle and shaded bar: CI-30 group; open triangle and gray bar: CI-180 group; closed diamond and diagonal bar: CLI-30 group; and open diamond 
and black dot bar: CLI‑180 group. Values are showed as mean ± standard error of mean, *vs. sham group (P<0.05); #vs. CS group (P<0.05); †vs. CI‑30 group 
(P<0.05); and ьvs. CLI‑30 group (P<0.05) (Tukey's test). CS, crush syndrome; CI, icing on whole hindlimb of CS rat; CLI, icing on local hindlimb of CS rat; 
BT, body temperature; MBP, mean blood pressure and HR, hart rate.
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Nakayama et al (17) reported that warming of the hindlimbs 
to 40˚C during compression resulted in a much lower survival 
rate and significantly enhanced hyperkalemia, leading to 
cardiac arrest. Therefore, lower BT and temperature of the 
affected muscle are believed to be necessary in improving 
hyperkalemia. However, icing treatment for 30 min signifi-
cantly increased the survival rate within 24 h from the injury; 
however, that with icing treatment for 180 min did not vary 
significantly despite a temporary decrease in serum potassium. 
The CS model rat in our study died from cardiac insuffi-
ciency following rapidly progressing (within an injured 3 h) 
hyperkalemia (5); nevertheless, the decreased survival period 
following hypothermia by the icing treatment for 180 min 
could not provide this reason. We believe that survival with CS 
state may be affected by various factors, such as hypovolemic 
shock and inflammation. Therefore, our findings suggest that 
icing therapy for 30 min effectively prolonged the viability in 
situations where the risk of hypothermia could be controlled, 
although, cooling of the affected limb is a simple therapy in 
difficult clinical situations with ongoing CS.
Interestingly, low tissue temperature can help in resisting 
hypoxia because chemical reactions in vivo are catalyzed 
by enzymes (18). Furthermore, this anti‑inflammation effect 
prevents leukocyte migration and edema by reducing vascular 
permeability (19). Icing treatment is not considered to be 
beneficial in the repair process of damaged tissue (8,20,21); 
however, uncontrolled inflammation is also harmful for 
homeostasis. We evaluated the overall balance between 
Table I. Effects of CS and icing therapy on blood gas parameters.
 Reperfusion (h)
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Parameter  0.083 0.5 0.1 3 6 24
pH 
  sham 7.48±0.02 7.46±0.01 7.46±0.03 7.48±0.00 7.50±0.01 7.45±0.01
  CS 7.44±0.02 7.51±0.03 7.43±0.02 7.38±0.02a 7.31±0.02a 7.22±0.05a
  CI‑30 7.45±0.04 7.42±0.03 7.44±0.02 7.43±0.03 7.40±0.00b 7.37±0.03b
  CI‑180 7.42±0.01 7.31±0.06b 7.33±0.03b 7.31±0.03 7.29±0.03 7.26±0.03
  CLI‑30 7.42±0.03 7.38±0.01 7.38±0.02 7.38±0.03 7.40±0.04b 7.37±0.03b
  CLI‑180 7.38±0.01b 7.37±0.02b 7.35±0.02b 7.30±0.03 7.27±0.03 7.30±0.04
BE (mmol/l) 
  sham 2.3±0.6 2.3±1.0 2.8±0.9 3.0±1.1 2.5±0.3 2.8±1.0
  CS 2.0±0.5 2.3±0.7 2.0±1.4 0.0±2.1 ‑5.0±0.7a ‑7.8±1.5a
  CI‑30 0.5±0.7 ‑2.3±1.0 ‑3.3±1.7 ‑5.0±2.0 ‑7.5±1.4 ‑6.3±1.2 
  CI‑180 0.5±0.6 ‑2.0±1.2 ‑1.5±1.1 ‑5.5±1.4 ‑6.0±0.8 ‑6.5±1.1
  CLI‑30 0.5±2.5 0.0±1.6 0.0±2.4 ‑4.8±3.5 ‑5.8±2.2 ‑4.8±1.7
  CLI‑180 ‑0.5±0.7 ‑1.8±0.7 ‑0.8±0.3 ‑3.8±0.3 ‑10.0±0.9b ‑9.5±0.3
AG (mmol/l) 
  sham 15.3±1.5 13.0±1.6 14.0±0.8 13.0±1.7 13.7±1.5 15.0±1.2
  CS 19.3±1.0 15.5±1.4 15.0±1.2 15.8±1.6 17.3±1.9 19.6±1.0
  CI‑30 16.0±2.3 18.8±1.3 18.5±1.5 18.5±1.1 19.0±0.7 19.5±0.7 
  CI‑180 20.8±1.5 18.5±0.6 16.3±0.9 18.5±1.4 19.3±1.1 18.8±0.6
  CLI‑30 18.0±1.6 15.8±1.8 15.8±1.4 17.8±1.2 19.8±1.7 21.0±1.7
  CLI‑180 20.8±1.7 16.8±1.1 14.5±2.0 16.5±1.7 19.8±0.6 21.5±1.7
Hct (%) 
  sham 45.0±1.2 46.8±1.3 47.3±1.7 46.5±1.4 46.3±1.3 46.0±1.7
  CS 45.0±1.2 46.5±0.3 47.5±0.3 52.0±1.2 56.0±1.8a 60.5±1.1a
  CI‑30 46.5±1.7 45.5±1.5 45.8±2.2 49.5±1.5 52.3±2.2 51.8±0.3 
  CI‑180 47.0±0.7 48.3±0.7 51.3±0.9 52.8±0.7 54.8±0.7 53.8±1.2
  CLI‑30 45.0±2.4 47.0±2.4 47.3±2.3 51.3±2.8 52.3±2.1 51.3±1.7
  CLI‑180 46.3±2.0 50.0±0.8 50.3±0.7 53.5±1.1 56.0±1.4 55.3±1.4
Values are presented as mean ± standard error in mean; avs. sham group and bvs. CS group (P<0.05) (Tukey's test). CS, crush syndrome; 
CI, icing over the entire hindlimb of CS rats; CLI, local icing over the affected hindlimb of CS rats; BE, base excess; AG, anion gap; Hct, 
hematocrit.
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Figure 3. Attenuation of hyperkalemia secondary to icing treatments. (A) plasma K+ level, (B) plasma CPK level, (C) the relationship between blood vessel 
BPF and muscle BPF levels and (D) laser doppler image showing the changes in an affected hindlimb. Scale bar=1 cm. White bar: Sham group; black bar: CS 
group; shaded bar: CI‑30 group; and diagonal bar: CLI‑30 group. Values are presented as mean ± standard error in mean; *vs. sham group (P<0.05); #vs. CS 
group (P<0.05) (Tukey's test). CS, crush syndrome; CI, icing over the entire hindlimb of CS rats; CLI, local icing over the hindlimb of CS rats; K+, potassium; 
CPK, creatine phosphokinase; BPF, blood perfusion.
Figure 4. Icing treatment was attenuated inflammation. (A) serum IL‑6, (B) serum IL‑10, (C) serum HMGB1 and (D) muscle tissue MPO activity. White bar: 
Sham group; black bar: CS group; shaded bar: CI‑30 group; and diagonal bar: CLI‑30 group. Values are showed as mean ± standard error in mean; *vs. sham 
group (P<0.05); #vs. CS group (P<0.05) (Tukey’s test). CS, crush syndrome; CI, icing over the entire hindlimb of CS rats; CLI, local icing of hindlimb of CS 
rats; IL, interleukin; HMGB1, high mobility group box protein 1; MPO, myeloperoxidase.
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inflammatory and anti‑inflammatory factors by assessing the 
serum levels of cytokines IL‑6 and IL‑10 (22), which are mark-
edly induced in CS rats. Additionally, we evaluated the serum 
levels of HMGB1, which is lethally involved in constitutive 
expression and vascular endothelial cell interactions (23,24), 
and is a lethal inflammation mediator (25). Extracellular 
release of HMGB1 induces the expression of adhesion factors 
of intravascular cells such as vascular cell adhesion molecule 
1, intercellular adhesion molecule 1, and E-selectin, and 
inflammatory reactions involving production of cytokines due 
to the extravasation of neutrophils and monocytes (23,26). 
As demonstrated by the MPO activity level in the muscle 
tissue, icing treatment suppresses both neutrophil infiltration 
and HMGB1 expression. The reduction in HMGB1, in turn, 
suppresses inflammation as indicated by lowered levels of IL‑6 
and IL‑10, which can also be due to inhibition of cell rupture. 
However, although IL‑10 is an anti‑inflammation cytokine, 
lowered levels of it seemed to be secondary to no expression due 
to suppression of inflammation. Additionally, icing treatment 
affects mitochondrial function after a long period of time. One 
of the characteristics of CS is that ROS production is enhanced 
in a relatively short time along with decreased mitochondrial 
function (6). In this study, ROS production peaked 6 h after 
the compression injury and was reduced by icing treatment. 
It is believed that this result is because of normalization of 
mitochondrial function and mitochondrial injury secondary to 
decreased cell temperature, as demonstrated by maintenance 
of the mitochondrial membrane potential (Fig. 5B) as well 
as cytoplasmic of cyt c (Figs. 5C and D). Therapeutic hypo-
thermia may also alleviate bursts of reactive oxygen species 
and calcium overload and activate the cell survival signaling 
pathways (26‑30), which are believed to be involved in perme-
ability transition pore (PTP) regulation (31‑33). Furthermore, 
some reports have suggested that therapeutic hypothermia 
limits calcium‑induced mitochondrial dysfunction, including 
opening of PTP (26,34,35).
In emergency situations, icing treatment following crush 
injury temporarily prolonged the viability by suppressing 
potassium elevation; however, this could not improve the 
overall outcomes dramatically because CS involves simulta-
neous and rapid worsening of multiple symptoms. Icing was 
suggested to be effective in suppressing the inflammatory 
reactions; therefore, the effectiveness of icing therapy can be 
enhanced by combining it with other infusion therapies.
Figure 5. Improving ROS generation and prevention of mitochondrial dysfunction in the crushed limb. (A) TBARS level, (B) JC‑l fluorescence, reflecting 
mitochondria membrane potential, (C) mitochondria cyt c content level and (D) cytoplasm cyt c content level in the crushed muscle tissue. White bar: Sham 
group; black bar: CS group; shaded bar: CI‑30 group; and diagonal bar: CLI‑30 group. Values are showed as mean ± standard error in mean; *vs. sham group 
(P<0.05) and #vs. CS group (P<0.05) (Tukey’s test). CS, crush syndrome; CI, icing over the entire hindlimb of CS rats; CLI, local icing over the hindlimb of 
CS rats; TBARS, thiobarbituric acid reactive substance; cyt c, cytochrome c.
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